EPIGEN BIOSCIENCES, INC.

Basic Information

10225 Barnes Canyon Road suite A104
SAN DIEGO, CA, 92121-2734

Company Profile

n/a

Additional Details

Field Value
DUNS: 963248807
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Synthesis and evaluation of novel kinase inhibitors as anti-metastasis agents for

    Amount: $225,000.00

    PROJECT SUMMARY Metastasis is a key factor for poor prognosis in cancer patients. Ovarian cancer is the fifth most common gynecological cancer causing significant mortality among women. Breast cancer ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Discovery of novel small molecule analgesics

    Amount: $244,999.00

    DESCRIPTION (provided by applicant): Peripheral nerve injury can lead to anomalous sensations referred to as neuropathic pain. Nerve injury may result from a variety of insults ranging from frank inju ...

    STTR Phase I 2014 Department of Health and Human Services
  3. Novel Therapeutic Opportunity in Stroke

    Amount: $225,000.00

    DESCRIPTION (provided by applicant): Stroke is a leading cause of death and disability in the USA, yet widely effective treatments remain elusive and, except for a lengthy program of rehabilitation, ...

    STTR Phase I 2014 Department of Health and Human Services
  4. High-specificity affinity reagents for N-glycosylation site mapping and glycomics

    Amount: $288,297.00

    DESCRIPTION (provided by applicant): Metastasis is a key factor for poor prognosis in cancer patients. Breast cancer is the most common invasive cancer in women and the second-most common cause of dea ...

    SBIR Phase I 2013 Department of Health and Human Services
  5. Drug regulators of nitric oxide production as Alzheimer's disease therapeutics

    Amount: $726,746.00

    DESCRIPTION (provided by applicant): Druggable regulators of nitric oxide production as new Alzheimer's disease therapeutics Summary: Nitrosative stress is a critical mediator of the onset and pr ...

    STTR Phase I 2012 Department of Health and Human Services
  6. Selective LPA1 receptor antagonists as agents in prevention of renal fibrosis

    Amount: $389,603.00

    DESCRIPTION (provided by applicant): The ultimate goal of our project is to develop novel therapeutics effective in chronic kidney diseases that normally develop fibrosis, lead to end stage renal dise ...

    SBIR Phase I 2012 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government